ArticleBlood cancer journal2025
Incidental vs. symptomatic diagnosis of follicular lymphoma: implications of earlier detection.
Article in Blood cancer journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Follicular lymphoma (FL) is usually diagnosed at an advanced stage when the patient presents with a palpable lymph node or symptoms such as pain and fatigue. However, due to advances in imaging techniques used for many diseases and cancer screening, incidental diagnosis of FL is expected to rise. In this study, we investigated FL disease characteristics and outcomes in patients diagnosed incidentally versus symptomatically, providing insights into what might be detected with multi-cancer early detection tests (MCEDs). We conducted a review of 908 patients with newly diagnosed FL enrolled in the Mayo Clinic component of the Molecular Epidemiology Resource (MER) from 2002 to 2015. We compared disease characteristics and outcomes between the incidental and symptomatic groups. Of the 908 patients, 259 (28.5%) were diagnosed incidentally. The incidental group was more likely to present with early-stage disease (stage I/II: 43.2% vs. 30.6%, p = 0.0003), normal lactate dehydrogenase (LDH) levels (87.2% vs. 80.8%, p = 0.03), and trended towards having lower FLIPI scores (49.8% vs. 42.2%, p = 0.1). However, there were no significant differences in event-free survival (EFS), overall survival (OS) or lymphoma-specific survival (LSS) between the two groups. In conclusion, incidental detection of FL is associated with earlier stages and more favorable disease characteristics. However, this did not translate into improved survival outcomes. Whether even earlier detection of FL using emerging MCEDs translates into improved outcomes remains an open question requiring further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.